J&J deepens its antiviral pipeline with Novira buyout

Johnson & Johnson is trading an undisclosed sum for private drugmaker Novira Therapeutics, picking up an early-stage treatment for hepatitis B and a handful of antivirals.

Eisai pairs up with a French research shop to find new cancer drugs

Japanese drugmaker Eisai has aligned itself with France's Paoli Calmettes Institute to spotlight potential oncology therapies.

Merck KGaA and Pfizer play catch-up in lung cancer with a Phase III immuno-oncology trial

Partners Merck KGaA and Pfizer are looking to prove their 5th-place immuno-oncology treatment can contend with the leaders in the field, launching a late-stage lung cancer study to establish the antibody's promise.

Brewis leaves GSK to take up CSO post at F-star

F-star has become the latest biotech to bag itself a Big Pharma exec. Neil Brewis is now heading up scientific operations at the immuno-oncology player, having previously served as GlaxoSmithKline's head of biopharmaceutical research.


A-list academic consortium snaffles €23M to take HIV vaccine into clinic

A consortium of top-tier European research centers has snagged €23 million ($25 million) to take a HIV vaccine toward the clinic. The Imperial College London-led project is drawing on the scientific capabilities of 23 research centers in an attempt to move a HIV vaccine into Phase I within the next 5 years.

Euro biotech IPOs smash through €1B barrier in just 9 months

European biotechs raised more than €1 billion ($1.1 billion) through IPOs in their home markets and overseas in the first 9 months of 2015, according to market analyst Biocom. But while the total represents an 18% increase over the same period of last year, a stuttering final quarter could cause 2015 to end with a whimper.

Allergan bets $50M on a dry eye drug as it touts its commitment to R&D

Allergan expanded its pipeline with a $50 million deal to bring in a late-stage treatment for dry eye as the company works to reaffirm its commitment to R&D in the face of industrywide scrutiny.

Vertex looks to gene therapy, RNA deals to quash takeover talk

Vertex is ready to get its checkbook out to quell talk of it being a takeover target for Biogen and Gilead. The plan is to use the cash flow from recently approved cystic fibrosis drug Orkambi to strike pipeline-broadening deals, with gene therapy and RNA two fields in the company's sights.

Biogen spells out its moonshot R&D strategy amid deep cost cuts

Biogen is in the midst of a wide-ranging reorganization that will send more than 800 employees out the door, but the company isn't backing away from its penchant for high-risk R&D, pressing forward with a pipeline focused on first-in-class therapies.

Flagship launches another microbiome biotech with $35M and a focus on cancer

Flagship Ventures, the group behind microbiome success story Seres Therapeutics, is delving further into gut science with a new startup that aims to treat cancer by harnessing the power of the body's many bacterial tenants.

Isis and GlaxoSmithKline eye Phase III with a rare disease drug

GlaxoSmithKline and partner Isis Pharmaceuticals are plotting a pivotal trial in the rare TTR amyloid cardiomyopathy, an inherited disease that impairs the heart muscle.

Two more biotechs queue up for IPOs as valuations waver

Boston biotech Wave Life Sciences and Australian regenerative medicine developer Mesoblast are the latest companies crowding into the ever-tightening IPO window for drugmakers, filing to make Nasdaq debuts amid diminishing returns for like-minded upstarts.

J&J and ViiV's long-acting HIV treatment stacks up to daily pills in Phase II

A new semimonthly treatment from Johnson & Johnson and ViiV Healthcare tamped down HIV as well as daily therapy in a midstage trial, promising a more convenient option for patients.

GSK forms Keytruda combo trial pact as it plots path to 20 filings by 2020

GlaxoSmithKline has struck a deal to trial its anti-OX40 monoclonal antibody in combination with Merck's Keytruda. The Phase I study is part of a slate of programs that GSK is hoping will support filings for up to 20 new drug approvals in the coming years, the success rate of which will go a long way to deciding whether the company can bounce back from its recent travails.

Sanofi inks a $1.5B deal to join BioNTech's growing list of oncology partners

Sanofi is pairing up with Germany's BioNTech in a collaboration potentially worth $1.5 billion, licensing some early-stage cancer immunotherapies that use messenger RNA to target tumors.

Gates, Hopp back $110M megaround for CureVac's mRNA work

The Bill & Melinda Gates Foundation joined German billionaire Dietmar Hopp in a venture syndicate that is injecting a whopping $110 million of fresh funds into CureVac, a German mRNA biotech which has now garnered some $330 million in support.

Boehringer expands its crowdsourced research to include psychiatric R&D

Boehringer Ingelheim has expanded its crowdsourced R&D program into the field of psychiatric diseases, broadening its partnership with Germany's BioMed X to spotlight new therapies.

Bristol-Myers bets $2B on Cardioxyl's heart failure therapy

Bristol-Myers Squibb is acquiring private biotech Cardioxyl Pharmaceuticals in a deal that could be worth more than $2 billion, bringing in a Phase II treatment for heart failure.

Shire is paying $5.9B for Dyax in a defensive rare disease deal

Shire signed a deal to buy Dyax for $5.9 billion, planning to snatch up a smaller competitor and fortify its rare disease business without taking its eyes off of acquisition target Baxalta.

Merck KGaA inks cancer metabolism drug discovery alliance with Selvita

Merck KGaA has teamed up with Selvita to discover small molecule drugs against multiple oncology indications. The alliance builds on an earlier two-year research collaboration into the discovery of enzyme inhibitors to regulate metabolic processes in cancer cells.